Soleus Capital Management, L.P. Galecto, Inc. Transaction History

Soleus Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.56 - $3.17 $57,312 - $324,427	-102,343 Reduced 10.23%	897,657 $646,000
Q2 2023 Aug 14, 2023	BUY	$1.68 - $2.84 $1.68 Million - $2.84 Million	1,000,000 New	1,000,000 $2.52 Million
Q3 2021 Nov 15, 2021	SELL	$3.59 - $5.0 $1.93 Million - $2.69 Million	-538,152 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.63 - $8.0 $4.51 Million - $7.8 Million	-974,496 Reduced 64.42%	538,152 $2.72 Million
Q4 2020 Apr 29, 2021	BUY	$12.51 - $16.84 $10.8 Million - $14.5 Million	863,048 Added 132.86%	1,512,648 $18.9 Million
Q4 2020 Feb 16, 2021	BUY	$12.51 - $16.84 $8.13 Million - $10.9 Million	649,600 New	649,600 $8.13 Million

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.